Market Overview

Wells Fargo Analyst Michael Ton Says Valeant May Have to Raise Offer for Obagi or Walk Away

Related VRX
Benzinga's Option Alert Recap From July 21
Jim Cramer Shares His Thoughts On VMware, Blue Apron, Valeant And Marriott Vacations

In a note from Wells Fargo analyst Michael Ton, concern is being raised over the current $19.75 per share offer from Valeant Pharmaceuticals (NYSE: VRX) for Obagi (NASDAQ: OMPI).

Concerns come from a recent offer by Merz Pharma, which may force Valeant to raise its offer, cut into margins or abandon the acquisition all together.

Tong went on to note that Valeant has a history of walking away from competitive bidding.

Following the news, Valeant Pharma traded roughly flat, while Obagi traded up 16.24 percent to $22.91.

Latest Ratings for VRX

Jul 2017Deutsche BankMaintainsHold
Jun 2017Cantor FitzgeraldInitiates Coverage OnOverweight
Dec 2016Morgan StanleyDowngradesOverweightEqual-Weight

View More Analyst Ratings for VRX
View the Latest Analyst Ratings

Posted-In: Analyst Color News M&A Analyst Ratings


Related Articles (OMPI + VRX)

View Comments and Join the Discussion!